Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01195727 · ClinicalTrials.gov registry record · Phase 1
Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01195727 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 13 participants.
The verdict
NCT01195727, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
CV185-079 is a multiple dose Apixaban Pharmacokinetics/Pharmacodynamics (PK/PD) study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects with a central venous catheter.
Interventions
- DRUG Apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-07-26 |
| Est. Completion | 2012-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01195727
The ClinicalTrials.gov registry entry for NCT01195727 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apixaban is the first listed.
NCT01195727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01195727 about?
NCT01195727 is a clinical study titled "Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter". CV185-079 is a multiple dose Apixaban Pharmacokinetics/Pharmacodynamics (PK/PD) study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects with a central venous catheter.
What is the current status of trial NCT01195727?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-07-26. Estimated completion is 2012-07-16.
What interventions are being tested in trial NCT01195727?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT01195727?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.